Castle Biosciences Wins NY Approval for AdvanceAD-Tx Test
FRIENDSWOOD, Texas, July 14, 2026 Castle Biosciences, Inc. has announced that its AdvanceAD-Tx™ test has received assay approval from...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
FRIENDSWOOD, Texas, July 14, 2026 Castle Biosciences, Inc. has announced that its AdvanceAD-Tx™ test has received assay approval from...
IRVING, Texas – May 4, 2026 Caris Life Sciences has secured MolDX approval for its flagship Caris ChromoSeq™ assay,...
South San Francisco, California, March 16, 2026 Veracyte, Inc. announced the appointment of Kevin Haas, Ph.D., as Chief Development...
HOUSTON, Texas, Feb. 16, 2026 — New data presented at the 2025 San Antonio Breast Cancer Symposium (SABCS) reveal...
